Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ibrutinib Monotherapy in Early Stage Chronic Lymphocytic Leukemia (CLL) Without IWCLL/NCI-WG 2008 Treatment Indications But With High-Risk Features for Disease Progression

NCT03207555 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03207555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03207555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ibrutinib Monotherapy in Early Stage Chronic Lymphocytic Leukemia (CLL) Without IWCLL/NCI-WG 2008 Treatment Indications But With High-Risk Features for Disease Progression
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
May 23, 2018
Completion date
August 2, 2024
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, malignant neoplasms stated as primary lymphoid haematopoietic, small lymphocytic leukemia